Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates.

Lanciotti J, Song A, Doukas J, Sosnowski B, Pierce G, Gregory R, Wadsworth S, O'Riordan C.

Mol Ther. 2003 Jul;8(1):99-107.

2.

PEGylated adenovirus for targeted gene therapy.

O'Riordan CR, Song A.

Methods Mol Biol. 2008;434:133-60. doi: 10.1007/978-1-60327-248-3_9.

PMID:
18470643
3.

Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.

Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR.

Hum Gene Ther. 1999 Nov 1;10(16):2615-26.

PMID:
10566889
4.

A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo.

Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, Meijer DK, Haisma HJ, Molema G.

Hum Gene Ther. 2004 May;15(5):433-43.

PMID:
15144574
5.

Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors.

Printz MA, Gonzalez AM, Cunningham M, Gu DL, Ong M, Pierce GF, Aukerman SL.

Hum Gene Ther. 2000 Jan 1;11(1):191-204.

PMID:
10646650
6.
7.

Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells.

Qin M, Escuadro B, Sharma S, Batra RK.

Am J Respir Cell Mol Biol. 2005 Mar;32(3):211-7. Epub 2004 Dec 30.

PMID:
15626775
8.

Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Pereboeva L, Komarova S, Roth J, Ponnazhagan S, Curiel DT.

Gene Ther. 2007 Apr;14(8):627-37. Epub 2007 Jan 25.

9.

Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy.

Wang W, Zhu NL, Chua J, Swenson S, Costa FK, Schmitmeier S, Sosnowski BA, Shichinohe T, Kasahara N, Chen TC.

J Neurosurg. 2005 Dec;103(6):1058-66.

PMID:
16381193
10.

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice.

Gu DL, Gonzalez AM, Printz MA, Doukas J, Ying W, D'Andrea M, Hoganson DK, Curiel DT, Douglas JT, Sosnowski BA, Baird A, Aukerman SL, Pierce GF.

Cancer Res. 1999 Jun 1;59(11):2608-14.

11.

Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.

Yao X, Yoshioka Y, Morishige T, Eto Y, Narimatsu S, Kawai Y, Mizuguchi H, Gao JQ, Mukai Y, Okada N, Nakagawa S.

Mol Ther. 2011 Sep;19(9):1619-25. doi: 10.1038/mt.2011.112. Epub 2011 Jun 14.

12.

Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models.

Van Houdt WJ, Wu H, Glasgow JN, Lamfers ML, Dirven CM, Gillespie GY, Curiel DT, Haviv YS.

Neuro Oncol. 2007 Jul;9(3):280-90. Epub 2007 May 23.

13.

Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.

Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piché A, Pierce GF, Alvarez RD, Siegal GP, Douglas JT, Curiel DT.

Clin Cancer Res. 1998 Oct;4(10):2455-61.

14.

Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.

Jung Y, Park HJ, Kim PH, Lee J, Hyung W, Yang J, Ko H, Sohn JH, Kim JH, Huh YM, Yun CO, Haam S.

J Control Release. 2007 Nov 6;123(2):164-71. Epub 2007 Aug 15.

PMID:
17854941
15.

PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability.

Eto Y, Gao JQ, Sekiguchi F, Kurachi S, Katayama K, Maeda M, Kawasaki K, Mizuguchi H, Hayakawa T, Tsutsumi Y, Mayumi T, Nakagawa S.

J Gene Med. 2005 May;7(5):604-12.

PMID:
15543536
16.

Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.

Wortmann A, Vöhringer S, Engler T, Corjon S, Schirmbeck R, Reimann J, Kochanek S, Kreppel F.

Mol Ther. 2008 Jan;16(1):154-62. Epub 2007 Sep 11.

17.

Targeting the CYP2B 1/cyclophosphamide suicide system to fibroblast growth factor receptors results in a potent antitumoral response in pancreatic cancer models.

Huch M, Abate-Daga D, Roig JM, González JR, Fabregat J, Sosnowski B, Mazo A, Fillat C.

Hum Gene Ther. 2006 Dec;17(12):1187-200.

PMID:
17069538
18.
19.

Targeted adenovirus vectors.

Mizuguchi H, Hayakawa T.

Hum Gene Ther. 2004 Nov;15(11):1034-44. Review.

PMID:
15610604
20.

Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.

Prill JM, Espenlaub S, Samen U, Engler T, Schmidt E, Vetrini F, Rosewell A, Grove N, Palmer D, Ng P, Kochanek S, Kreppel F.

Mol Ther. 2011 Jan;19(1):83-92. doi: 10.1038/mt.2010.229. Epub 2010 Oct 19.

Supplemental Content

Support Center